Desogestrel

證據等級: L5

預測適應症: 10 個

Desogestrel: From Contraception to Acne

One-Sentence Summary

Desogestrel is a third-generation progestogen widely used as a component of combined oral contraceptives for pregnancy prevention. The TxGNN model predicts it may be effective for Acne, with 1 completed clinical trial and 20 publications currently supporting this direction. Among 10 predicted indications, acne stands out as the most evidence-supported candidate with a clear mechanistic rationale involving anti-androgenic effects on sebaceous gland activity.

Quick Overview

Item	Content
Original Indication	Contraception (oral contraceptive progestogen)
Predicted New Indication	Acne
TxGNN Prediction Score	99.91%
Evidence Level	L2 (1 completed Phase 4 RCT)
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Desogestrel is a third-generation gonane progestogen that acts as a prodrug — it is converted in the body to its biologically active metabolite, etonogestrel (3-keto-desogestrel). Etonogestrel binds the progesterone receptor with high selectivity and has notably lower androgenic activity compared to older progestogens such as levonorgestrel. When combined with ethinylestradiol in oral contraceptive formulations, the combination suppresses ovarian androgen production and markedly increases sex hormone-binding globulin (SHBG), thereby reducing circulating free testosterone levels.

Acne vulgaris is an androgen-dependent condition. Excess androgens stimulate sebaceous gland activity, increase sebum production, and contribute to follicular hyperkeratinisation — all key steps in acne pathogenesis. The mechanistic link between desogestrel-containing oral contraceptives and acne improvement is well-established: by suppressing free testosterone and reducing sebaceous gland stimulation, these formulations address a root hormonal driver of acne. Multiple clinical studies have confirmed that desogestrel/ethinylestradiol combinations reduce acne lesion counts, lower serum androstenedione and testosterone, and improve clinical acne grading in women with mild-to-moderate acne vulgaris.

This makes the TxGNN prediction highly plausible. In fact, combined oral contraceptives containing third-generation progestogens (including desogestrel) are already recognised internationally as a treatment option for hormonal acne in women, though this specific indication is not formally registered for desogestrel-containing products in all jurisdictions.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01466673	Phase 4	Completed	201	Direct head-to-head comparison of EE/norgestimate vs EE/desogestrel for treatment of mild-to-moderate acne vulgaris in women. Evaluated efficacy and safety of both regimens as acne therapy.

Note: Only 1 registered clinical trial was identified directly comparing desogestrel-containing oral contraceptives for acne treatment. However, the extensive literature base (below) includes multiple clinical studies that evaluated acne outcomes as primary or secondary endpoints.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8894800	1996	Comparative trial	Int J Fertil Menopausal Stud	Compared desogestrel-containing OC (Marvelon) vs cyproterone acetate (Diane) for acne in Oriental women; both formulations effective.
8689881	1996	Clinical study	Contraception	EE/gestodene vs EE/desogestrel in 19 women with acne: both reduced androstenedione, testosterone, and free androgen index; acne improvement observed.
2956138	1987	Clinical study	Eur J Obstet Gynecol Reprod Biol	EE/desogestrel in oligomenorrhoeic adolescents with hyperandrogenism: significant reductions in LH, testosterone, androstenedione, and DHEA-S after 6 months.
2976224	1988	Clinical study	Acta Eur Fertil	EE/desogestrel in hyperandrogenic and normal adolescents: acne improved within 12 months; low side-effect incidence.
8200468	1994	Clinical study	Eur J Obstet Gynecol Reprod Biol	Biphasic EE/desogestrel OC in 33 acne patients: effective on endocrine correlates of hyperandrogenism; significant SHBG increase and free androgen reduction.
6084924	1984	Clinical study	Acta Derm Venereol	Desogestrel/EE vs levonorgestrel/EE in 54 female acne patients: desogestrel formulation produced greater SHBG increase and free testosterone reduction.
3161265	1985	Pharmacodynamic study	Acta Obstet Gynecol Scand Suppl	Evaluated androgenicity of progestogens with focus on desogestrel; demonstrated lower androgenic activity compared to older progestins.
12566804	2003	Review	Dermatology	Systemic acne treatment update: oral contraceptives with anti-androgenic progestins (including desogestrel) recommended for papulopustular and hormonal acne.
7825629	1995	Review	Am J Med	Comprehensive review of progestin androgenicity: desogestrel classified among newer progestins with reduced androgenic effect.
8178905	1994	Review	Am J Obstet Gynecol	Clinical and metabolic profile of desogestrel: highly selective gonane progestin with favourable tolerability and non-contraceptive benefits including acne improvement.

South Africa Market Information

Desogestrel is currently not registered with SAHPRA (South African Health Products Regulatory Authority). There are no active marketing authorisations for desogestrel-containing products in South Africa.

Implication for repurposing: Before desogestrel can be considered for acne treatment in South Africa, a SAHPRA registration (either as a new application or via Section 21 access) would be required. Healthcare professionals should note that desogestrel-containing products are widely available internationally (e.g., Marvelon, Mercilon, Cerazette) and are registered in multiple regulatory jurisdictions.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information once the product is registered. In the interim, prescribers should consult international regulatory references (e.g., EMA SmPC, FDA labelling) for comprehensive safety data. Report adverse drug reactions to SAHPRA.

Key considerations from international labelling (for reference):

Combined oral contraceptives containing desogestrel carry a known risk of venous thromboembolism (VTE), with third-generation progestogens associated with a slightly higher VTE risk compared to second-generation formulations
Contraindicated in women with a history of or current VTE, known thrombophilia, migraine with aura, breast cancer, or severe hepatic disease
Drug interactions include reduced contraceptive efficacy with CYP3A4 inducers (e.g., rifampicin, certain anticonvulsants, St John’s Wort)

Other Predicted Indications Summary

The TxGNN model generated 10 predicted indications for desogestrel. Besides acne, the table below summarises the remaining predictions and their assessment:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Rationale
1	Amenorrhoea	99.96%	L4	Hold	Paradoxical: desogestrel POP actually causes amenorrhoea in 20–30% of users; association ≠ treatment
2	Apocrine adenosis of breast	99.92%	L5	Hold	Benign breast lesion; no evidence for progestogen treatment
3	Blunt duct adenosis of breast	99.92%	L5	Hold	Same score as #2; likely same knowledge graph node cluster
5	Breast abscess	99.89%	L5	Hold	Infectious condition requiring antibiotics/drainage; no mechanistic basis
6	Fat necrosis of breast	99.89%	L5	Hold	Physical trauma-related condition; no hormonal treatment basis
7	Lactation disease	99.87%	L4	Hold	Desogestrel is safe during lactation, but does not treat lactation disorders
8	Breast adenosis	99.85%	L5	Hold	Benign breast proliferation; no treatment evidence
9	Primary ovarian failure	99.72%	L5	Research Question	Partial rationale — desogestrel could theoretically serve as HRT progestogen component, but natural progesterone preferred
10	Fragile X syndrome (female carrier)	99.55%	L5	Hold	Extremely weak link via FXPOI; core neurological symptoms unrelated to progestogens

Pattern observation: Multiple breast-related conditions (ranks 2, 3, 5, 6, 8) received high TxGNN scores despite absent evidence, suggesting the model detects structural proximity between hormonal drug nodes and breast disease nodes in the knowledge graph rather than genuine therapeutic relationships.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The repurposing of desogestrel (in combination with ethinylestradiol) for acne treatment is supported by a completed Phase 4 RCT (n=201) and a robust body of clinical literature spanning nearly four decades. The mechanistic rationale is clear and well-validated: desogestrel-containing OCs reduce circulating free androgens via SHBG elevation and ovarian androgen suppression, directly addressing a key driver of acne pathogenesis. This indication is already recognised in international clinical guidelines, making this a low-risk repurposing candidate with strong translational potential.

To proceed, the following is needed:

SAHPRA registration pathway: Determine whether to pursue full registration or Section 21 access for desogestrel-containing products in South Africa
Mechanism of action data: Obtain complete MOA documentation from DrugBank to formalise the pharmacological rationale
Safety profile: Obtain full Professional Information (PI) including warnings, contraindications, and drug interactions — particularly regarding VTE risk in the South African population
Local clinical context: Assess the prevalence of hormonal acne in South African women and determine where desogestrel-containing OCs would fit within existing SAHPRA-approved acne treatment pathways
Essential Medicines List consideration: Evaluate whether inclusion on the South African EML is appropriate given the dual contraceptive/dermatological benefit

Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application. All predictions are generated by the TxGNN computational model and should be interpreted in conjunction with clinical judgement.

Report generated: 2026-04-05 | Evidence Pack version: v4 | Data cutoff: 2026-04-05

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.